Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology
Go back to Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 107.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $107.62 | 52 Week High | $18.39 | |||
| Open | $107.62 | 52 Week Low | $6.96 | |||
| Day High | $107.62 | P/E | N/A | |||
| Day Low | $107.62 | EPS | $-0.58 | |||
| Volume | 273 | |||||
